Transdermal Delivery System for Hormones and Steroids
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
DHEA | Medchemexpress
Inhibitors Product Data Sheet DHEA • Agonists Cat. No.: HY-14650 CAS No.: 53-43-0 Molecular Formula: C₁₉H₂₈O₂ • Molecular Weight: 288.42 Screening Libraries Target: Androgen Receptor; Endogenous Metabolite Pathway: Others; Metabolic Enzyme/Protease Storage: Please store the product under the recommended conditions in the Certificate of Analysis. SOLVENT & SOLUBILITY In Vitro DMSO : 50 mg/mL (173.36 mM; Need ultrasonic) Ethanol : 50 mg/mL (173.36 mM; Need ultrasonic) H2O : 1 mg/mL (3.47 mM; Need ultrasonic) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 3.4672 mL 17.3358 mL 34.6717 mL Stock Solutions 5 mM 0.6934 mL 3.4672 mL 6.9343 mL 10 mM 0.3467 mL 1.7336 mL 3.4672 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: Cremophor EL Solubility: 14.29 mg/mL (49.55 mM); Clear solution; Need ultrasonic 2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 4. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 5. Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.67 mM); Clear solution 6. -
Abnormal Uterine Bleeding: Strategies for Management”
PRE-CONGRESS COURSE 4 SIG Endometriosis & Endometrium “Abnormal uterine bleeding: strategies for management” CONTENTS Program overview p. 1 Speakers’ contributions • Abnormalities of menstrual bleeding: getting our terminologies right - I. Fraser (AUS) p. 3 • Abnormal uterine bleeding: the patient perspective - P. Warner (UK) p. 13 • Optimising strategies for evaluation and management of abnormal uterine bleeding - A. Prentice (UK) p. 32 • Unscheduled bleeding with exogenous hormone administration – P. Rogers (AUS) p. 33 • Strategies to control; endometrial bleeding - D. Archer (USA) p. 46 • Local mechanisms responsible for endometrial bleeding - H. Critchley (UK) p. 49 • Is there a role for selective progesterone receptor modulators in management of uterine bleeding? - K. Chwalisz (USA) p. 61 • Should menstruation be optional? – Health benefits of amenorrhoea – D. Baird (UK) p. 72 PRE-CONGRESS COURSE 4 - PROGRAMME SIG Endometriosis & Endometrium Abnormal uterine bleeding: strategies for management Course co-ordinators: H. Critchley (UK) & Th. D’Hooghe (B) Course description: Problematic uterine bleeding impairs quality of life for many women and often involves invasive treatments and significant cost. Agreement is needed on terminology and defi nitions in order to facilitate the establishment of multi-centre clinical trials evaluating the strategies for management. Contemporary management also requires an understanding of the patient’s perspective of her complaint and an understanding of acceptability to women of the available modes of investigation and treatment options. Optimal therapies will only be possible with a detailed understanding of the mechanisms involved in endometrial bleeding including unscheduled bleeding with exogenous hormone administration. Novel therapies need to be evaluated in the context of potential health benefits from therapies that reduce the number of menstrual cycles experienced by women. -
And Active-Controlled Phase 3 Study of Postmenopausal Women with Osteoporosis
Christiansen et al. BMC Musculoskeletal Disorders 2010, 11:130 http://www.biomedcentral.com/1471-2474/11/130 RESEARCH ARTICLE Open Access SafetyResearch article of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis Claus Christiansen*1, Charles H Chesnut III2, Jonathan D Adachi3, Jacques P Brown4, César E Fernandes5, Annie WC Kung6, Santiago Palacios7, Amy B Levine8, Arkadi A Chines8 and Ginger D Constantine8 Abstract Background: We report the safety findings from a 3-year phase 3 study (NCT00205777) of bazedoxifene, a novel selective estrogen receptor modulator under development for the prevention and treatment of postmenopausal osteoporosis. Methods: Healthy postmenopausal osteoporotic women (N = 7,492; mean age, 66.4 years) were randomized to daily doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or placebo for 3 years. Safety and tolerability were assessed by adverse event (AE) reporting and routine physical, gynecologic, and breast examination. Results: Overall, the incidence of AEs, serious AEs, and discontinuations due to AEs in the bazedoxifene groups was not different from that seen in the placebo group. The incidence of hot flushes and leg cramps was higher with bazedoxifene or raloxifene compared with placebo. The rates of cardiac disorders and cerebrovascular events were low and evenly distributed among groups. Venous thromboembolic events, primarily deep vein thromboses, were more frequently reported in the active treatment groups compared with the placebo group; rates were similar with bazedoxifene and raloxifene. Bazedoxifene showed a neutral effect on the breast and an excellent endometrial safety profile. The incidence of fibrocystic breast disease was lower with bazedoxifene 20 and 40 mg versus raloxifene or placebo. -
PEMD-91-12BR Off-Label Drugs: Initial Results of a National Survey
11 1; -- __...._-----. ^.-- ______ -..._._ _.__ - _........ - t Ji Jo United States General Accounting Office Washington, D.C. 20648 Program Evaluation and Methodology Division B-242851 February 25,199l The Honorable Edward M. Kennedy Chairman, Committee on Labor and Human Resources United States Senate Dear Mr. Chairman: In September 1989, you asked us to conduct a study on reimbursement denials by health insurers for off-label drug use. As you know, the Food and Drug Administration designates the specific clinical indications for which a drug has been proven effective on a label insert for each approved drug, “Off-label” drug use occurs when physicians prescribe a drug for clinical indications other than those listed on the label. In response to your request, we surveyed a nationally representative sample of oncologists to determine: . the prevalence of off-label use of anticancer drugs by oncologists and how use varies by clinical, demographic, and geographic factors; l the extent to which third-party payers (for example, Medicare intermediaries, private health insurers) are denying payment for such use; and l whether the policies of third-party payers are influencing the treatment of cancer patients. We randomly selected 1,470 members of the American Society of Clinical Oncologists and sent them our survey in March 1990. The sam- pling was structured to ensure that our results would be generalizable both to the nation and to the 11 states with the largest number of oncologists. Our response rate was 56 percent, and a comparison of respondents to nonrespondents shows no noteworthy differences between the two groups. -
Adrenal Disorders
Adrenal Disorders Dual-release Hydrocortisone in Addison’s Disease— A Review of the Literature Roberta Giordano, MD,1 Federica Guaraldi, MD,2 Rita Berardelli, MD,2 Ioannis Karamouzis, MD,2 Valentina D’Angelo, MD,2 Clizia Zichi, MD,2 Silvia Grottoli, MD,2 Ezio Ghigo, PhD2 and Emanuela Arvat, PhD3 1. Department of Clinical and Biological Sciences; 2. Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences; 3. Division of Oncological Endocrinology, Department of Medical Sciences, University of Turin, Turin, Italy Abstract In patients with adrenal insufficiency, glucocorticoids (GCs) are insufficiently secreted and GC replacement is essential for health and, indeed, life. Despite GC-replacement therapy, patients with adrenal insufficiency have a greater cardiovascular risk than the general population, and suffer from impaired health-related quality of life. Although the aim of the replacement GC therapy is to reproduce as much as possible the physiologic pattern of cortisol secretion by the normal adrenal gland, the pharmacokinetics of available oral immediate-release hydrocortisone or cortisone make it impossible to fully mimic the cortisol rhythm. Therefore, there is an unmet clinical need for the development of novel pharmaceutical preparations of hydrocortisone, in order to guarantee a more physiologic serum cortisol concentration time-profile, and to improve the long-term outcome in patients under GC substitution therapy. Keywords Addison’s disease, glucocorticoids, hydrocortisone, Plenadren®, limits, advantages Disclosure: The authors have no conflicts of interest to declare. Received: June 28, 2013 Accepted: August 9, 2013 Citation: US Endocrinology 2013;9(2):177–80 DOI: 10.17925/USE.2013.09.02.177 Correspondence: Roberta Giordano, MD, Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, Azienda Ospedaliera Città della Salute e della Scienza di Torino, C so Dogliotti 14, 10126 Turin, Italy. -
Campro Catalog Stable Isotope
Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information .............................................................................................. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors
This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. Research Articles: Cellular/Molecular Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors Kelsey A. Rankin1, Feng Mei1, Kicheol Kim1, Yun-An A. Shen1, Sonia R. Mayoral1, Caroline Desponts2, Daniel S. Lorrain2, Ari J. Green1, Sergio E. Baranzini1, Jonah R. Chan1 and Riley Bove1 1University of California, San Francisco, Weill Institute for Neurosciences, Department of Neurology 2Inception Sciences, San Diego, CA https://doi.org/10.1523/JNEUROSCI.1530-18.2019 Received: 11 June 2018 Revised: 17 January 2019 Accepted: 20 January 2019 Published: 29 January 2019 Author contributions: K.R., Y.-A.A.S., A.J.G., J.R.C., and R.B. designed research; K.R., F.M., K.K., Y.- A.A.S., S.R.M., C.D., D.S.L., and S.B. performed research; K.R. analyzed data; K.R. wrote the first draft of the paper; K.R., J.R.C., and R.B. edited the paper; K.R. wrote the paper; F.M. and J.R.C. contributed unpublished reagents/analytic tools. Conflict of Interest: The authors declare no competing financial interests. We would like to thank the Innovation Program for Remyelination and Repair at the Weill Institute for Neurosciences at the University of California, San Francisco (UCSF). This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01NS062796, R01NS097428, R01NS095889, R01NS088155], the National Multiple Sclerosis Society [RG5203A4], The Adelson Medical Research Foundation: ANDP (A130141), the Heidrich Family and Friends and the Rachleff Family Endowments. -
Frequently Asked Questions for Addison Patients
FREQUENTLY ASKED QUESTIONS FOR ADDISON PATIENTS TABLE OF CONTENT (Place your cursor over the subject line, hold down the Control Button and Click your mouse. To get back to the Table of Content, hold down the Control Button and press the Home key) ADDISONIAN CRISIS / EMERGENCY ADDISONS AND OTHER DISORDERS ADDISONS AND OTHER MEDICATIONS ADRENALINE BLOOD PRESSURE COMMON COLD/FLU/OTHER ILLNESS CORTISOL DAY CURVE CORTISOL MEDICATION CRAMPS DIABETES DIAGNOSING ADDISONS EXERCISE / SPORTS FATIGUE FLORINEF / SALT / SODIUM HERBAL / VITAMIN SUPPLEMENTS HYPERPIGMENTATION IMMUNIZATION MENOPAUSE, PREGNANCY, HORMONE REPLACEMENT, BIRTH CONTROL, HYSTERECTOMY MISCELLANEOUS OSTEOPOROSIS SECONDARY ADDISON’S SHIFT WORK SLEEP 1 STRESS DOSING SURGICAL, MEDICAL, DENTAL PROCEDURES THYROID TRAVEL WEIGHT GAIN 2 ADDISONIAN CRISIS / EMERGENCY How do you know when to call an ambulance? If you are careful, you should not have to call an ambulance. If someone with adrenal insufficiency has gastrointestinal problems and is unable to keep down their cortisol or other glucocorticoid for more than 24 hrs, they should be taken to an emergency department so they can be given intravenous solucortef and saline. It is not appropriate to wait until they are so ill that they cannot be taken to the hospital by a family member. If the individual is unable to retain anything by mouth and is very ill, or if they have had a sudden stress such as a fall or an infection, then it would be necessary for them to go by ambulance as soon as possible. It is important that you should have an emergency kit at home and that someone in the household knows how to use it. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
Edinburgh Research Explorer Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women Citation for published version: Brache, V, Sitruk-Ware, R, Williams, A, Blithe, D, Croxatto, H, Kumar, N, Kumar, S, Tsong, Y-Y, Sivin, I, Nath, A, Sussman, H, Cochon, L, Miranda, MJ, Reyes, V, Faundes, A & Mishell, D 2012, 'Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women', Contraception, vol. 85, no. 5, pp. 480-8. https://doi.org/10.1016/j.contraception.2011.10.003 Digital Object Identifier (DOI): 10.1016/j.contraception.2011.10.003 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Contraception Publisher Rights Statement: NIH Public access author manuscript General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2013 May 01. -
Us Anti-Doping Agency
2019U.S. ANTI-DOPING AGENCY WALLET CARDEXAMPLES OF PROHIBITED AND PERMITTED SUBSTANCES AND METHODS Effective Jan. 1 – Dec. 31, 2019 CATEGORIES OF SUBSTANCES PROHIBITED AT ALL TIMES (IN AND OUT-OF-COMPETITION) • Non-Approved Substances: investigational drugs and pharmaceuticals with no approval by a governmental regulatory health authority for human therapeutic use. • Anabolic Agents: androstenediol, androstenedione, bolasterone, boldenone, clenbuterol, danazol, desoxymethyltestosterone (madol), dehydrochlormethyltestosterone (DHCMT), Prasterone (dehydroepiandrosterone, DHEA , Intrarosa) and its prohormones, drostanolone, epitestosterone, methasterone, methyl-1-testosterone, methyltestosterone (Covaryx, EEMT, Est Estrogens-methyltest DS, Methitest), nandrolone, oxandrolone, prostanozol, Selective Androgen Receptor Modulators (enobosarm, (ostarine, MK-2866), andarine, LGD-4033, RAD-140). stanozolol, testosterone and its metabolites or isomers (Androgel), THG, tibolone, trenbolone, zeranol, zilpaterol, and similar substances. • Beta-2 Agonists: All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Most inhaled beta-2 agonists are prohibited, including arformoterol (Brovana), fenoterol, higenamine (norcoclaurine, Tinospora crispa), indacaterol (Arcapta), levalbuterol (Xopenex), metaproternol (Alupent), orciprenaline, olodaterol (Striverdi), pirbuterol (Maxair), terbutaline (Brethaire), vilanterol (Breo). The only exceptions are albuterol, formoterol, and salmeterol by a metered-dose inhaler when used